long-term symptoms reported by cancer survivors and improve their quality of life.
Electroencephalography (EEG) biofeedback or neurofeedback is a scientifically based technique that can allow the brain to learn self-regulation skills. 22 These skills have clinical relevance and changes in brain regulation will be manifested in symptomatic and subjective changes. During neurofeedback, brain activity is monitored through electrodes placed on the scalp and fed back to the participant through auditory and/or visual stimuli generated through computer software without introducing anything intrusive into the brain. 23 Rather, neurofeedback provides new information, which can open up the brain to options within its own control; if the changes result in a new stable state, or one that provides continued benefits to the participant, then it will continue to be reinforced after the session is over. 22 The mechanism of action is generally considered to be operant conditioning in which the brain is retrained to function in healthier brainwave patterns. 24 The process is often described as exercise for the brain, which increases the efficiencies of specific brain function and enhances cognitive flexibility and control. 24 Meditation, relaxation, martial arts, yoga, and cognitive training are other ways of gaining control over one's mental state; however, neurofeedback is usually more rapid and efficient. 25 
Brain Waves and Neurofeedback Approaches
The cyclical electrical activation and deactivation of neurons in the brain can be recorded as raw unfiltered brain wave signals by EEG. 26 These EEG signals can be amplified and filtered into smaller parts, called frequencies that are used during neurofeedback. Neurofeedback delivers feedback at the time of the cycle when the brain wave moves into a desirable pattern, providing simple reinforcement that teaches the brain to prolong healthy brain wave patterns. Each frequency can be measured in terms of its speed in hertz (Hz) or cycles per second, and amplitude (height of the wave) measured in microvolts (µV). Slow frequencies (<10 Hz) tend to have higher amplitudes than faster frequencies (>13 Hz) but not always. 26 Single frequencies have been organized into discreet groups called bandwidths that are associated with specific characteristics: delta (1-4 Hz) associated with sleep, repair, complex problem solving; theta (4-8 Hz) associated with creativity, insight, deep states; alpha (8) (9) (10) (11) (12) Hz) associated with alertness, peacefulness; beta (13) (14) (15) (16) (17) (18) (19) (20) (21) Hz) associated with thinking, focusing, sustained attention; sensorimotor rhythm (SMR; 12-15 Hz) associated with mental alertness, physical relaxation; high beta (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) Hz) associated with intensity, hyperalertness, anxiety; and gamma (38) (39) (40) (41) (42) Hz) associated with cognitive processing and learning. 26 There appears to be no single conceptual model to describe the processes and outcomes of neurofeedback among practitioners or manufacturers. 27, 28 As a result, numerous nonspecific (placebo/expectancy, client/therapist/family variables/interactions), treatment-specific (treatment protocols), neurophysiological and psychological factors have been used to explain how neurofeedback is effective in the treatment of a wide variety of symptoms and disorders. 29 Neurofeedback training is generally aimed at changing the amplitude (inhibition or augmentation) of selected frequency bandwidths through the principles of operant and classical conditioning; however, there are numerous approaches and protocols that can be used.
Alpha/theta training involves promotion of lower EEG frequencies for experiential and integrative purposes. 30 This deep-states training is commonly used for alcoholism and posttraumatic stress disorder (PTSD). 31 SMR/beta training involves training to improve physiological selfregulation, and functional normalization and optimization. 30 The most common neurofeedback training approaches can generally be grouped under 3 guiding philosophies. (1) Targeted mechanisms-based, symptomresponsive approaches in which the neurofeedback provider selects a reinforcement brainwave target for the specific symptom are typically applied to traditional psychopathologies such as anxiety, depression and bipolar disorders, attention disorders, personality disorders, trauma recovery, addictions, pain syndromes, sleep disorders, and specific learning disabilities 32 ; (2) QEEG-driven approaches that seek EEG normalization based on stationary QEEG measures are typically applied to more severely affected clinical populations such as neurological problems, traumatic brain injuries, strokes, seizures, dementias, developmental delay, cerebral palsy, and autism; 32 and (3) nonlinear dynamical (NLD) approaches that are generalized approaches to neuroregulation based on the theory of nonlinear dynamical systems 27 are generally applied to nonclinical populations for optimum mental fitness, brain exercise and meditation practice. 30 However, all 3 approaches can be effective in all these domains. 32 Other nontraditional neurofeedback approaches can also be used. A low-energy neurofeedback system (LENS) approach uses weak electromagnetic signals to provide feedback to the brain. 33 Like NLD neurofeedback, LENS use a nonspecific treatment approach that is not guided by diagnosis. 33, 34 Hemoencephalography (HEG) neurofeedback or cerebral flow neurofeedback, is used to train individuals to improve cerebral blood flow to key areas of the brain which improves cerebral oxygenation and translates into enhanced mental capacity. 35 HEG uses physiological signals based on blood flow dynamics rather than electrical activity and is reported to be particularly helpful with head injuries, attention deficit disorder and migraines. 35, 36 
Clinical Applications of Neurofeedback
Biofeedback has recently been recognized by the American Academy of Pediatrics as a "Level 1-Best Support" intervention for attention and hyperactivity behaviors. 37 Neurofeedback is also reported to help with a variety of conditions, including chronic pain, chronic fatigue syndrome, depression, anxiety disorders, sleep disorders, PTSD, migraines, and cognitive decline. 21 It is unclear whether cancer survivors experiencing similar symptoms would benefit from neurofeedback and which approaches or protocols would be most effective for managing cancer fatigue and cognitive impairment.
In the Canadian Cancer Society pamphlet Complementary Therapies: A Guide for People With Cancer, biofeedback is described as a type of mind-body therapy used to improve quality of life. 38 In a clinical practice guideline for integrative oncology, mind-body modalities of CAM therapies are recommended for reducing anxiety, mood disturbance, and chronic pain and for improving quality of life in cancer patients; these techniques include meditation, hypnosis, relaxation, cognitive-behavioral therapy, biofeedback, and guided imagery. 39 A published study protocol describes a clinical trial that will investigate the effectiveness of neurofeedback using SMR/beta training to improve neurocognitive functioning of children treated for a brain tumor. 40 Results from a recent prospective study by Alvarez et al 41 demonstrated the feasibility of neurofeedback for breast cancer survivors. The sample initially demonstrated significant dysfunction compared with general population norms prior to neurofeedback, and strongly significant improvements (P < .001) postneurofeedback on all 4 cognitive measures, a fatigue scale, 4 psychological scales, and 3 of 8 sleep scales; improvements were generally linear across the course of training, and were maintained at follow-up testing. 41 These results suggested neurofeedback deserved further study as a novel, method of addressing long-term symptoms in cancer survivors that may be safe, effective, and acceptable to patients.
Unfortunately, neurofeedback is not widely accepted by the general public or medical community because of lack of information and insufficient research to demonstrate its benefits, and lack of coverage by public or private health insurance plans. 42 The Canadian Integrative Oncology Research Initiative identified 5 interrelated priority research areas, including clinical effectiveness and safety of complementary therapies. 43 Information about which neurofeedback technologies and protocols are being used successfully and with minimal side effects is needed.
Purpose
The purpose of this review was to explore the effect and safety of EEG biofeedback or neurofeedback on fatigue and cognitive impairment which are long-term symptoms commonly experienced by cancer survivors. The review attempted to answer the following research questions:
1. What is the effect of neurofeedback on fatigue and cognition? 2. What side effects and/or adverse events are experienced during or following neurofeedback therapy administered for management of fatigue or enhancing cognition? 3. Which neurofeedback systems, approaches and/or protocols have demonstrated effectiveness for management of fatigue and/or enhancing cognition?
Methods

Data Sources
This systematic review was conducted using Joanna Briggs Institute (JBI) methodology, including JBI critical appraisal and data extraction tools. 44 The research team had experience in review methodologies and was supported by a library scientist. Inclusion criteria were defined a priori. A comprehensive systematic search of 5 databases was con- A study was eligible for inclusion in this review if it (1) reported on adult cancer survivors, individuals with other chronic health conditions or nonclinical populations seeking to decrease fatigue and/or enhance cognitive abilities;
(2) reported results of randomized controlled trials, nonrandomized controlled trials, controlled before and after studies, cohort, case control, or descriptive studies that assessed effectiveness and/or safety of EEG biofeedback or neurofeedback therapy; and (3) was written in English. We excluded studies on children, editorials, reviews, expert opinion papers, and studies published as abstracts only.
Study Selection and Critical Appraisal
Titles and abstracts were screened to determine broad eligibility using the inclusion and exclusion criteria. All citations identified as "include for critical appraisal" or "unclear" were rescreened using full text reports. Papers selected for critical appraisal were assessed by the principal investigator (MLF) and another reviewer (DG or LP) for methodological quality prior to final inclusion in the review. One of 3 JBI standardized critical appraisal instruments were used depending on the study design: (1) JBI Critical Appraisal Checklist for Experimental Studies 45 ; (2) JBI Critical Appraisal Checklist for Comparable Cohort/Case Control Studies 46 ; or (3) JBI Critical Appraisal Checklist for Descriptive/Case Series. 47 Given the paucity of research in this area, a cutoff score of 4 was established for each JBI checklist to ensure a sufficient number of studies to review while maintaining the strength of the methodological quality. A score of 4 to 6 indicated moderate quality, whereas as score of 7 or more indicated high quality. See the diagram in Figure 1 for a summary of the search decision flow.
Data Extraction, Synthesis, and Analysis
The primary reviewer (MLF) extracted data from the 17 included studies using a modified JBI data extraction form to summarize the pertinent details from each study. Extracted data were transferred to synopsis tables to synthesize relevant data. Because this systematic review was conducted using JBI methodology, the results were presented in separate tables by study design (ie, experimental vs descriptive studies). The data extracted included the following specific details of significance to the review questions and objectives: reference, study design, patient population/sample, neurofeedback intervention (system, protocols, number of sessions), outcome measures, efficacy results, safety results, limitations, conclusions, study quality. The primary outcomes of interest were levels of chronic fatigue and cognitive impairment. Secondary outcomes of interest were side effects and adverse events. Given the heterogeneity of the intervention systems and protocols, no meta-analysis was conducted. 
Results
Quality Assessment
Twenty-seven relevant studies were included in the critical appraisals. The quality of most studies was poor to moderate based on the JBI critical appraisal checklists. Seventeen studies were deemed of sufficient quality to be included in the review. Of these, only 2 were rated as high-quality studies, 45, 46 and the remaining were rated as moderate quality. [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] Findings Ten experimental studies (see Table 1 ) and 7 descriptive studies (see Table 2 ) were synthesized in this review.
Characteristics of the Included Studies
The 17 included studies were published in English between 2000 and 2013 in 7 countries. Ten of the studies were conducted in the United States. 41, 45, 47, 49, [54] [55] [56] [57] [58] [59] and 1 each from Mexico, 48 Austria, 50 Turkey, 51 Germany, 52 France, 53 and England. 46 Seven of the 10 experimental studies were randomized controlled trials, 45, 46, [48] [49] [50] [51] 54 and 3 had quasiexperimental study designs. 47, 52, 53 The descriptive studies consisted of 4 uncontrolled case series, 56-59 2 pre-post studies, 41, 60 and 1 case-control study. 55 Six studies reported on results with patients with traumatic brain injuries, 52,54,57-60 3 with fibromyalgia, 45,51,55 1 with breast cancer survivors, 41 1 with patients with central nervous system (CNS) problems, 41,55-60 and 1 with medical students having high withdrawal scores. 46 Additionally, 5 studies reported on results with nonclinical populations. Three studies were conducted with healthy elderly persons, 47,48,53 1 with healthy adults, 50 and 1 with healthy college students. 49 Sample sizes ranged from 6 to 64 for the experimental studies and from 5 to 100 for the descriptive studies. Participant ages ranged from 19 to 84 years for the experimental studies and from 6 to 80 years for the descriptive studies.
Neurofeedback Interventions Used in the Included Studies
A wide variety of neurofeedback systems and technology were used in the included studies, however they can be grouped into 5 general types of neurofeedback training. Four experimental studies used alpha/theta training [46] [47] [48] 53 ; 4 experimental studies [49] [50] [51] [52] and 1 observational study 55 involved SMR/beta training; 4 descriptive studies involved QEEG training 57-60 ; 1 descriptive study employed an NLD approach 41 ; and 2 experimental studies 45, 54 and 1 descriptive study 56 used a LENS approach. None of the studies reported on HEG biofeedback. Interventions ranged from 4 to 98 neurofeedback sessions 1 to 5 times per week, with most studies reporting from 10 to 40 sessions delivered once or twice per week.
Effect on Fatigue and Cognition
All the included studies reported positive results for at least 1 fatigue or cognitive outcome as measured by a variety of standard self-rating questionnaires and cognitive task tests. Fourteen of the studies reported improvements in cognition, 41, 45, [47] [48] [49] [52] [53] [54] [55] [56] [57] [58] [59] [60] and 8 of the studies reported improvements in fatigue. 41, 46, [49] [50] [51] [54] [55] [56] Alpha/theta training demonstrated mixed results on cognitive performance in three experimental studies with healthy elderly subjects. In the pilot study by Angelakis et al, 47 a peak alpha frequency (PAF) neurofeedback protocol resulted in improvement in speed of processing and executive functioning but had no clear effect on memory, whereas an alpha magnitude protocol showed improvement in memory. In the study by Becerra et al, 48 healthy seniors improved on 2 measures from the Wechsler Adult Intelligence Scale (WAIS-III), Verbal Comprehension (P = .02) and Verbal IQ (P = .05) as well as the total score on the NEUROPSI neuropsychological test battery (P = .01), which evaluates attention, executive function, and memory. The Memory Score of the NEUROPSI increased significantly in both the experimental and control groups (P = .01). Improved memory performance (P = .01) as measured by the Signoret Memory Battery was observed in members of all 3 treatment groups in the study by Lecomte and Juhel, 53 which compared neurofeedback (NFB) to relaxation and a test/retest (TRT) group. Memory performance of several NFB participants improved significantly more than the average increase of increase observed in the TRT group (P = .001 to P = .022). Raymond et al 46 reported that medical students with high withdrawal scores given reported feeling more energetic (P < .01) given alpha/theta neurofeedback, and that participants given mock feedback felt more tired (P < .05).
Sensorimotor rhythm/beta training resulted in a significant main effect (P < .05) among a sample of nonclinical psychology students for the Integrated Variables of Attention Full-Scale Response Quotient (IVA FSRQ), which measures response control (response accuracy, impulsivity, and fatigue). 49 Instrumental conditioning of SMR resulted in improved declarative memory performance in a study with healthy individuals as evidenced by higher retrieval scores on the Wechsler Memory Scale-Revised after only 10 sessions (P = .018). 50 Two studies reported on the use of SMR training for individuals with fibromyalgia. Kayiran et al 51 reported significantly lower VAS-fatigue scores following SMR training versus patients treated with escitalopram. Fibromyalgia patients in the study by Caro and Winter 55 reported 40% improvements in fatigue as measured by a subjective 0 to 10 scale (P = .006) and significant improvements in attention on 4 of 6 Continuous Performance Test (CPT) subscores (P < .01). A sample of patients with traumatic brain injury improved more in a sustained attention task following beta activity training than a control group who received computer-based attention training (P = .006).
Quantitative EEG training improved cognitive measures in 4 studies of patients with brain injuries. Two case series studies by Thornton 57, 58 reported improvements in memory ranging from 39% to 181% as measured by story/paragraph recall. A third, larger study by Thornton and Carmody 59 recorded 105% improvements in auditory memory and 143% improvements in reading memory among the traumatic brain injury subjects. Significant memory improvement (>50%) was noted in 88% of mild closed head injury patients as measured by the Global Improvement Score (GIS) in a pre-post study by Walker et al. 60 All the patients in the study reported being able to return to work following the QEEG neurofeedback therapy.
Nonlinear dynamical training was reported in only 1 study, a pre-post study with a wait-list control in which Alvarez et al 41 Low-energy neurofeedback system training was effective in a randomized controlled trial of 64 persons with fibromyalgia as rated by clinicians on the Clinical Global Impressions Scale-Clinician (CGI-I) at session 22 (P = 0.01) and follow-up (P = .04), but there was no significant effect on the participant version of the scale (PGI-I) or the Cognitive Fatigue Fibromyalgia Symptom Scales or the Fibromyalgia Impact Questionnaire (FIQ) or the CNS Dysfunction Questionnaire. 45 LENS was also used in a smaller trial with traumatic brain injury patients. 54 The therapy resulted in significant improvements on some measures of cognitive function involving working memory versus a 6-to 8-week wait-list control group: Digit Span Backwards (P < .05), Interference Trial (P < .05), Delayed Recall Trial (P < .03) of the Auditory Verbal Learning Test (AVLT), and the most difficult trial of the Paced Auditory Serial Addition Test (PASAT; P < .02). Fatigue scores also improved significantly as measured by the Individualized Symptom Rating Scale (P < .01) and the General Fatigue and Mental Fatigue subscales (P < .02) of the Multidimensional Fatigue Inventory (MFI) in comparison with the control group. An uncontrolled case series of 100 subjects with CNS problems demonstrated that LENS therapy was clinically effective with mean symptom ratings on the Subjective Symptom Rating Scale (SSRS) at posttreatment falling to exactly half of the pretreatment levels (P < .001). 61 The top four r 2 values in rank order of improvement were disorganization (.985), cognitive problems (.983), attention (.956), and fatigue (.955). Executive function ranked eighth (.903).
Safety of Neurofeedback
Only 4 of the included studies commented on the side effects or safety of the neurofeedback interventions. Angelakis et al 47 indicated that some neurofeedback protocols may worsen some performance items. In the RCT by Kravitz et al, 45 side effects were monitored at each session, with 52.5% of subjects reporting at least 1 side effect at any time during the treatment. Side effects differed significantly (P < .007) between the LENS treatment group (74.2%) and the control group (35.7%) with the most commonly reported symptoms being fatigue, pain, sleep problems, and stiffness and muscle spasms. No subjects dropped out of the study due to side effects, however, in a few cases the therapy was temporarily suspended. The most common side effect experienced in the LENS trial by Schoenberger et al 54 was a temporary intensification of previously problematic symptoms such as pressure in the head or headache, dizziness, nausea, tingling sensation, or physical pain associated with injuries. These reactions typically occurred within the first six or seven sessions and resolved within a few days. Fatigue and restlessness were the most common indications of overtreatment and session length was reduced accordingly. And finally, in the pre-post trial of breast cancer survivors conducted by Alvarez et al, 41 the NLD neurofeedback approach was well tolerated and none of the participants reported any side effects or adverse effects.
Discussion
The aim of this review was 3-fold: (1) to describe the effect of neurofeedback on fatigue and cognition, (2) to describe side effects and/or adverse events experienced during or following neurofeedback therapy administered for management of fatigue or enhancing cognition, and (3) to describe neurofeedback systems, approaches and/or protocols that have demonstrated effectiveness for management of fatigue and/or enhancing cognition.
Research dating back to the 1940s has demonstrated that brainwave or EEG activity could be trained through classical and operant conditioning using biofeedback techniques. 62 Clinical applications have ensued in the fields of neurology and psychology, protocols and equipment have been refined, and evidence has been building for its use in treatment of epilepsy, attention deficit disorder, closed head injury, learning disabilities, anxiety, depression, alcoholism and other addictions and autism spectrum disorders. 63 Research studies have also reported that neurofeedback helps with chronic pain, chronic fatigue syndrome, sleep disorders, PTSD, migraines, and cognitive decline. 21 As evidenced by the retrieval of only a single completed study 41 and a single RCT protocol 40 investigating effectiveness of neurofeedback for cancer survivors experiencing cancer fatigue or cognitive impairment, the results of this review demonstrate that the field of oncology has not yet evaluated this noninvasive therapy, which has the potential to ameliorate symptoms in cancer patients and cancer survivors. All the included studies related to fatigue and cognition were published since 2000, suggesting this area of research is relatively new. However, each of these studies reported positive results for at least 1 fatigue or cognitive outcome in a variety of clinical (traumatic brain injury, fibromyalgia, CNS problems) and nonclinical (college students, adults, elderly) populations. Despite relatively small sample sizes, statistically significant results were obtained. This suggests that neurofeedback addresses an underlying mechanism for fatigue and cognition common to these different issues or is responsive to a variety of neuropsychological pathologies either through targeted or generalized approaches.
Results of this review are consistent with reports in the literature that describe neurofeedback as safe and well tolerated. Although only 4 studies commented on side effects, none of the studies reported subjects dropping out due to side effects. Neurotherapy rarely produces negative side effects, which is a major reason for its use. 28 Adverse effects reported in the literature appear to be associated with volitional types of neurofeedback protocols that attempt to push the brain in specific directions, which can occasionally result in side effects and when improperly done, exacerbation of symptoms. 64 In the case of nonvolitional neurotherapy, such as NLD approaches, the practitioner does not push the brain in any particular direction but cues the brain to strengthen its own self-regulatory networks. 32 Reported side effects seem to be exacerbation of existing symptoms or complaints, and are usually very transient, dropping away after only a few sessions. These results are consistent with findings of a survey of providers using an NLD system. 65 Of the 3 studies included in this review that reported side effects or adverse effects, 1 study involved peak alpha frequency training 47 and 2 involved LENS therapy. The peak alpha training pushed the brain in a specific direction, which improved some cognitive measures at the expense of visual memory. 47 The LENS neurofeedback interventions, which are nonvolitional, resulted in transient exacerbation of symptoms such as fatigue and pain. Participants in the single NLD neurofeedback study did not report any side effects.
There appears to be no single conceptual model to describe the process and outcomes of neurofeedback among practitioners or manufacturers. 26, 27 In this review, a variety of neurofeedback systems, approaches and protocols were employed for the purpose of ameliorating symptoms of chronic fatigue and improving cognition. All of the included studies reported positive results for at least one fatigue or cognitive outcome suggesting that multiple approaches may be effective.
The lone study that evaluated neurofeedback with breast cancer survivors, although not an RCT, demonstrated promising results using an NLD approach: 23 women demonstrated significant improvements on all 4 cognitive measures and the fatigue scale after only 20 sessions with no side effects, adverse effects or dropouts reported. These results suggest that the NLD approach warrants further study through randomized controlled trials and larger sample sizes to confirm efficacy and safety as well as to establish the optimum range or number of sessions required to achieve lasting results. Overall, results suggest that protocols for any of the neurofeedback approaches should include a minimum of 10 to 20 sessions to demonstrate effectiveness, recognizing that individuals may require fewer or more sessions to alleviate their symptoms.
This systematic review was conducted using JBI methodology, which includes studies using different research designs. Different appraisal tools are used to evaluate studies that are experimental (randomized control/pseudorandomized trial) versus observational/descriptive studies. Although observational/descriptive studies cannot be used to determine causation, they suggest relationships that could be further investigated through RCTs if appropriate, and thus were in included in this review, which explores a novel intervention that has not been well researched.
Collectively, results of the studies included in this review represent at best level 2 evidence due to the inclusion of several small RCTs and quasi-experimental studies according to the JBI levels of evidence in which level 1 evidence, the strongest evidence would consist of results of a meta-analysis (with homogeneity) of experimental studies or one or more large experimental studies with narrow confidence intervals. 44 
Limitations
The greatest limitation of this review is the small sample sizes used in both the experimental and descriptive studies. Confounding factors such as concurrent medication use were often not described. Methodological quality of the majority of the studies was only moderate, with few blinded, RCTs included. Use of different outcome measurement tools limits the ability to make comparisons between different neurofeedback protocols and approaches. As well the diversity of neurofeedback approaches and systems makes it difficult to categorize and explain the overall positive results.
Conclusions
Despite issues with methodological quality, the overall positive findings and few reported side effects associated with neurofeedback for fatigue and cognitive impairment suggest this innovative CAM therapy could be helpful in alleviating these symptoms. Currently, there is insufficient evidence that neurofeedback is an effective therapy for management of fatigue and cognitive impairment in cancer survivors; however, these promising results support the need for further research with this patient population. More information about which neurofeedback technologies, approaches and protocols could be successfully used with cancer survivors and with minimal side effects is needed. Clinical trials comparing the effectiveness of specific neurofeedback protocols and approaches to sham neurofeedback and/or to other neurofeedback protocols are urgently needed to move this field forward. Trials should also compare neurofeedback with other approaches that encourage healthy self-regulation of the brain such as physical activity and mindfulness-based stress reduction strategies. Study limitations that should be addressed in future research include use of randomization and double-blinding, larger sample sizes and increased statistical power to increase the quality of individual studies as well as the overall level of evidence to efficacy and safety of various neurofeedback approaches.
This review will provide preliminary data on which to build a protocol for a pilot RCT in a sample of cancer survivors to determine feasibility, recruitment strategies, validate instruments, and establish effect size for calculation of sample size for a larger clinical trial to evaluate the effectiveness and safety of neurofeedback in this population. In the long term, the proposed program of research may help cancer survivors with long term symptoms for whom other approaches have failed, or who do not want to continue to use medications, as well as provide scientific evidence of efficacy. The results will have significance to nurses and physicians in oncology and primary care settings who provide follow-up care and counseling to cancer survivors experiencing debilitating symptoms such as cognitive impairment (chemobrain) and cancer fatigue.
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